NeuroSense Therapeutics - Unit
NRSN----
NeuroSense Therapeutics - Unit (NRSN)
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenera...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
NeuroSense Therapeutics - Unit Analyst Rating
View MoreForecast & Rating
Jul 23, 2026Price forecast
$6.50892.37%
Forecast & RatingStrong buy
3analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · 1 day ago, 07:31 AM
NeuroSense plans PrimeC new drug filing with Health Canada for ALS
- StockTitan · Jul 5 at 11:45 PM
NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS" | NRSN Stock News
- StockTitan · Jun 29 at 12:30 AM
NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS | NRSN Stock News
- Tip Ranks · Jun 25 at 08:50 AM
NeuroSense Posts Positive Phase 2 Biomarker Signals for PrimeC in Alzheimer’s Trial
- PUBT · Jun 22 at 08:03 AM
NeuroSense joins EverythingALS community event on PrimeC data in ALS
